Dr. Lin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
MDA
Houston, TX 77030- Is this information wrong?
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2014 - 2017
- Case Western Reserve University School of MedicineClass of 2014
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2023 - 2026
- TX State Medical License 2018 - 2025
- TN State Medical License 2023 - 2025
- LA State Medical License 2023 - 2024
- MS State Medical License 2023 - 2024
- WA State Medical License 2023 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsImpact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transp...Kamal Alzahrani, Oren Pasvolsky, Zhongya Wang, Denái R Milton, Mark R Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Hans C Le...> ;British Journal of Haematology. 2024 Mar 6
- 1 citationsAuthor Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.Ye Li, Rafet Basar, Guohui Wang, Enli Liu, Judy S Moyes, Li Li, Lucila N Kerbauy, Nadima Uprety, Mohsen Fathi, Ali Rezvan, Pinaki P Banerjee, Luis Muniz-Feliciano, Tam...> ;Nature Medicine. 2024 Mar 1
- 7 citationsSafety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19B cell tumors: a phase 1/2 trial.David Marin, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, Merve Dede, Yago Nieto, Nadima Uprety, Sunil Acharya, Enli Liu, Jeffrey Wilson, P...> ;Nature Medicine. 2024 Mar 1
- Join now to see all
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: